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INTRODUCTION
Cervical cancer is one of the major leading causes
of death among women due to cancer. It is the
second most common cancer on women in the
world, of which 83% of that occurs in developing
countries.1,2 In Indonesia, the incidence of cervical
cancer is estimated to be 100 per 100,000
populations among 79-million women at risk. The
mortality rate of cervical cancer in Indonesia is
very high because more than 70% of cases are
diagnosed at advanced stage.3
This cancer is actually highly preventable due to
known etiologic causes. The main factor
Abstract
Objective: To analyze level of retinol deposit sufficiency in the
natural history of cervical cancer.
Methods: Serum retinol level was measured by ELISA from
peripheral blood of subjects with normal cervix, cleared and
persistent high risk human papilloma virus (HR-HPV) subclinical
infection, and cervical cancer who fulfilled the inclusion and
exclusion criteria. The study was held in Dr. Cipto Mangunkusumo
and Fatmawati Hospital, Jakarta, within 2 years (August 2013-
2015). Blood was taken twice, consisting of post-8-hour fasting
blood and 2 hours after 6000 IU retinyl palmitate oral
administration.
Results: Of 47 total samples, sufficient level of retinol deposit in
normal cervix, cleared and persistent HR-HPV subclinical infection,
and cervical cancer group was 85.0% (reference), 75.0% (OR 1.89),
33.3% (OR 11.33), and 75% (OR 1.89); respectively. Statistically,
there was no significant difference from sufficiency level of retinol
deposit between normal cervix and clearance HR-HPV subclinical
infection (p=0.628), normal cervix and persistent HR-HPV
subclinical infection (p=0.078), normal cervix and cervical cancer
(p=0.433), cervical cancer and clearance HR-HPV subclinical
infection (p=1.000), cervical cancer and persistent HR-HPV
subclinical infection (p=0.430), persistent and clearance HR-HPV
subclinical infection group (p=0.740).
Conclusion: This study proves that normal cervix group has the
highest level of retinol deposit sufficiency; however, it cannot
be stated that cervical cancer group has less sufficiency level.
Persistent HR-HPV subclinical infection group has the lowest
level of retinol deposit (OR 11.33). There is no association
between sufficient level of retinol deposit and clearance of
HR-HPV.
[Indones J Obstet Gynecol 2017; 5-1: 46-54]
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Abstrak
Tujuan: Untuk menganalisis tingkat kecukupan deposit retinol pada
perjalanan alami kanker serviks.
Metode: Kadar retinol serum diperiksa dari darah perifer dengan
metode ELISA pada kelompok serviks normal, infeksi subklinishuman papilloma virus risiko tinggi (HPV-RT) klirens dan
persisten, serta kanker serviks yang sesuai dengan kriteria
inklusi dan eksklusi di Rumah Sakit Dr. Cipto Mangunkusumodan Fatmawati, Jakarta, pada periode 2 tahun (Agustus 2013-
2015). Sampel darah diambil dua kali yaitu setelah puasa 8 jamdan 2 jam setelah pemberian 6000 UI retinil palmitat peroral.
Hasil: Diperoleh 47 sampel total dari 4 kelompok yang diteliti. Depositretinol yang cukup pada kelompok serviks normal, infeksi subklinis
HPV-RT klirens, HPV-RT persisten, dan kanker serviks adalah
berturut-turut 85%, 75% (OR 1,89), 33,3% (OR 11,33), dan 75%(OR1,89). Secara statistik tidak terdapat perbedaan bermakna tingkat
kecukupan deposit retinol antara kelompok serviks normal denganinfeksi subklinis HPV-RT klirens (p=0,628), serviks normal dengan
infeksi subklinis HPV-RT persisten (p=0,078), serviks normal dengan
kanker serviks (p=0,433), kanker serviks dengan infeksi subklinisHPV-RT klirens (p=1,000), kanker serviks dengan infeksi subklinis
HPV-RT persisten (p=0,430), infeksi subklinis HPV-RT persisten
dengan klirens (p=0,740).
Kesimpulan: Penelitian ini mampu membuktikan bahwa tingkatkecukupan deposit retinol tertinggi dijumpai pada kelompok serviks
normal, namun tidak mampu membuktikan bahwa kanker serviks
memiliki tingkat kecukupan deposit retinol yang kurang.Tingkatkecukupan deposit retinol terendah ditemukan pada kelompok HPV
persisten (OR 11,33). Tidak terdapat hubungan antara deposit retinol
yang cukup dengan klirens HPV-RT.
[Maj Obstet Ginekol Indones 2017; 5-1: 46-54]
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contributing to cervical cancer is persistent
infection of high risk-human papillomaviruses
(HR-HPVs) ,  which  is  the  precursor  for
malignancy. The hypothesis was a relationship
between HPV infection and cervical neoplasia
which was first introduced by Harold zur-Hausen
as a German virologist.4-6
Although HPV has been identified as the cause
of cervical cancer, most women infected with HPV
do not always develop to be cervical cancer. Most
of them, around 70-90% of cases, will experience
a clearance. Therefore, this issue leads to the idea
that there are other factors contributing to the
induction of cancer other than HPV infection.7
Local immune response is a determining factor that
affects its susceptibility to HPV and progression
into cervical cancer.8,9 In individuals who
have competent immune system, most HPV
infections occur subclinically, and only small
percentage will progress to pre-cancerous lesions
and invasive cervical cancer. The mechanisms of
HPV in keeping off the immune response are due
to the modulation of cytokines to alter antigen
presentation, interferon (IFN) regulatory
pathways, and adhesion molecules. The
avoidance of HPV to immune response is a
critical point of the successful HPV infection to
host cells.10
Nutritional cofactors, which are associated with
immunity, have an important role in the defense
against HPV infection. Various antioxidants have
been known to boost the immune system against
viruses and other microorganisms, as well as
tumor cells. Retinol, as cofactor nutrient, is
essential in cervical mucosal immunity. It is able to
modulate the non-specific and specific immune
system against HPV infection and tumor cells.11 It
also has central role in growth, development and
differentiation of B and T lymphocytes, and as
major regulator of cell activation on immune
system.12 The CD4+T and CD8+T cells can be
modulated by retinol. T-cell is specific to the virus
and protective factor against tumor cells.
Meanwhile, CD8+T-lymphocytes or Cytotoxic
T-Lymphocyte (CTL) assited by molecular Major
Histocompatibility Complex (MHC) class I acts to
recognize and kill tumor cells. CD4+T-cells are
generally not cytotoxic to the tumor, they may play
an important role in anti-tumor response
by producing cytokines which are necessary for
the development of CTL cells into effector cells, yet.
CD8+T-cells can eliminate viral infection by
secreting IFN-, and granzyme, to run cytolytic
effect.13
Retinol is a potent HPV and carcinogenesis
inhibitor. It acts mainly by three mechanisms,
such as apoptosis, cessation of growth, and
differentiation.14 Retinol can inhibit cells
immortalization by HPV; thus, retinol offers
protective effect against the occurrence of cervical
neoplasia.11
In the cervix, retinol can interact with HPV
oncoprotein (E6 and E7) and increase the role of
p53 and pRb (tumor suppression genes) to control
cell cycle and proliferation. Retinol can inhibit not
only early gene expression of HPV types 16 to 95%
by lowering E2 and E5 mRNA, but also E6 and E7
proteins. It can lower the level of viral oncogenes
transcription and inhibit neoplastic process.
Retinol can protect the mucosa against viral
infection and it has a cytostatic effect by inducing
the cessation of cell cycle-dependent p53,14
generating CD4+T-cells, inducing effective
CD8+T-cells responses, suppressing inflammatory
cells, and producing several cytokines, including
tumor necrosis factor-alpha (TNF-) which are
potent to control HPV infection.15-17
The transformation zone of cervix is a high-risk
zone that can be altered by HPV infection. This
zone is also the most sensitive zone to retinol.
Retinol increases resistance to infectious micro-
organism by maintaining the function, structure of
epithelial cells, mucosal integrity, and stabilization
of inter-cell linkage. When retinol is absent, goblet
cells will disappear and mucosal epithelial atrophy
will occur. Therefore, it will lead to irritation and
infection.18
Until now, there has been no recommendations
of retinol to increase the clearance of HPV infection
as well as improve the response of cervical cancer
therapy clinically. Apart from that, retinol is very
cheap so that the cost problem will be minimally
debated. This study aims to analyze the adequacy
of retinol deposit on the natural history of cervical
cancer, ranging from normal cervix, cleared and
persistent subclinical HPV infection, to cervical
cancer. To determine the adequacy status of retinol
level in this study, we measured through level of
deposit in the liver by the relative dose response
(RDR) method in examination of retinol-binding
protein 4 (RBP4) at fasting and 2 hours after
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administration of retinylpalmitate. The RBP4 is also
popular as plasma retinol-binding protein which
transports  ret inol  in  serum.  Ret inol  is
metabolized into retinaldehyde as some isomers of
retinoic acid and retinyl esters. Retinaldehyde is
important chromophore in rhodopsin photo-
receptor; whereas, retinoic acid regulates many
cellular differentiation and proliferation effects via
intracellular receptors retinoic acid receptor (RAR)
and retinoic X receptor (RXR). The RBP4 adopts
-barrel structure with a central cavity that
accommodates either retinol or retinaldehyde and
it is synthesized primarily in hepatocytes and
adipocytes as 21 kDa non-glycosylated molecules,
non-phosphorylated, and non-sulfate.
According to aspect of nutrition, the lack of
retinol is associated with cervical cancer; thus, it is
that it can be used as a basic approach to primary
prevention of cervical cancer. Giving retinol is
expected to reduce the risk of persistent HR-HPV
infection and progression towards pre-
cancerous lesions and cervical cancer.
Eventually, it can reduce the incidence, morbidity,
and mortality of cervical cancer.
METHODS
This study consisted of four groups representing
the natural history of cervical cancer, such as the
normal cervix, persistent subclinical HPV infection,
HPV clearance, and cervical cancer. Normal cervix
consisted of subjects with normal cervical cytology
result and negative HPV DNA test. Cervix with
subclinical HPV infection included those with
negative cytology result and positive HR-HPV DNA
test. Cervical cancer was expressed through the
result of squamous cell carcinoma (SCC) type
according to histopathology assessment. Normal
group and cervical cancer data were taken cross
sectionally; whereas, subclinical infection with
HR-HPV clearance and persistent were coming
from population with positive HR-HPV followed by
continuous checking twice in 12-24 months. We
recruited subjects from August 2013 to August
2015.
Inclusion and Exclusion Criteria
The target population of this study was
reproductive age women with negative cytology
result or without positive HPV or cervical cancer.
We included all  women coming to the
Gynecologic Oncology Clinic, Department of
Obstetrics and Gynecology, Dr. Cipto Mangun-
kusumo and Fatmawati Hospital during the study
period who f u l f i l l e d  t h e  i n c l u s i o n  a n d
exclusion criteria. Inclusion criteria for this
study consisted of sexually active women aged
20-60 years old with negative cytology result,
or SCC proven by histopathology assessment
and they agreed to participate in the study.
While, the exclusion criteria were married
women under the age of 20 years old, having
multiple sexual partners, having malnutrition,
on pregnancy, having a history of intravenous
narcotics use, promiscuity confession, using long
term steroid agents or intrauterine device
( I U D ) ,  a n d  experiencing genitourinary tract
infection.
Patient Enrollment
During the period of August 2013 until August
2015, we obtained 71 samples among 538
potential subjects for subclinical HR-HPV infection
clearance and persistent group. Subject with
normal cervix (control), clearance, and persistent
group taken from Women’s Health Clinic (WHC),
Dr. Cipto Mangunkusumo Hospital in Kencana
Cluster. While, we got cervical cancer group from
WHC outpatient clinic, Gynecologic Oncology
outpatient and inpatient, Department of Obstetrics
and Gynecology, Dr. Cipto Mangunkusumo and
Fatmawati hospital. Due to several reasons related
to geographical problem of their living area, we
successfully recruited 7 women (9.9%) for
subclinical HR-HPV infection clearance and
persistent group. Initially, we took 22 samples for
control group; however, two samples were
excluded because of sample lysis and HPV-positive
result after re-checking. There were four subjects
for subclinical HR-HPV infection clearance group
and three subjects for persistent group. There were
27 samples for cervical cancer group, seven
samples were excluded due to lysis, yet.
Laboratory Protocol
We examined the samples through sandwich
ELISA. The manufacturer kit  R&D system
instructed this method. To determine the status of
the retinol adequacy, we measured the level of
retinol deposit in the liver by Relative Dose
Response (RDR) method through examination of
serum retinol-binding protein 4 (RBP4) at fasting
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and 2 hours after administration of 6,000 IU of
retinylpalmitate orally. Retinol deposit is defined
to be sufficient if there is an increase of RBP4 of
less than 20%, insufficientcy if there is an increase
of more than or equal to 20%.
Blood sampling was performed using EDTA
tubes after signing the informed consent. The
ELISA plates coated with antibodies of RBP4 were
used. The blood samples were centrifuged to
separate serum from red blood cell at a speed of
3,500 rpm for 10 minutes. Serum was collected and
placed in a threaded tube and stored at -80°C. The
serum, standard and control, was put in each plate
as much as 20 l with previously added diluent
200 l. After that, the plate was incubated in an
o r b i t a l  s h a k e r  f o r  o n e  h o u r  a t  r o o m
temperature. After an hour, the plate was washed
three times using 400 l buffer solution. The next
step was to provide as much as 200 l conjugate
RBP4, then incubated for one hour and continued
by washing the plate. The final step was the
addition of 200 l substrate solution and incubated
for 30 minutes. To stop the reaction, fifty
microliters stop solution were given. At this time,
the color of the solution would turn into yellow.
We utilized a microplate reader Glo-Max at a wave
length of 450 nm to read and interpret the result.
Statistical Analysis
We used SPSS version 20.0 to analyze the data. The
association between groups with sufficiency level
of retinol deposit was analyzed as unpaired
categorical comparative table. We used chi-square
analysis resulting in the odds ratio (OR) and
confidence interval (CI) 95%. To avoid multiplicity,
chi-square and odds ratio were calculated with
logistic regression procedure.
RESULTS
Over 2 years of period, from August 2013 to August
2015, forty-seven samples were obtained. The
characteristics of the subjects were presented in
Table 1.
According to the table, it could be seen that the
average age of subjects with cervical cancer,
cleared and persistent subclinical HR-HPV
infection, and normal cervix (control) were 48.5,
40.0, 46.0, and 41.0 years old, respectively. The
mean age of first marriage was regarded as the first
sexual contact when relatively young, which all
results showed for more than 20 years old. Most
of the subjects and their partners were married
only once; and most of them had low parity. Almost
all subjects did not smoke. Based on these
demographic characteristics, the subjects in this
study had lower risk factors for HPV infection and
cervical cancer.
Meanwhile, the deposit adequacy level of retinol
was shown in Table 2. Of 47 total samples, retinol
deposit sufficiency level in normal cervix,
subclinical HPV infection clearance, persistent, and
cervical cancer group was 85.0% (reference),
75.0% (OR 1.89), 33.3% (OR 11.33), and 75% (OR
1.89), respectively.
Table 1. Demographic Characteristics
Variables Cervical cancer(n = 20) Persistent HPV(n = 3) HPV clearance(n = 4) Control(n = 20)
Age (years old) 48.5  9.5 40.0  10.0 46.0  5.0 41.0  16.0
The age of first marriage (years old) 21.5  1.5 21.5  0.5 23.0  3.0 24.0  3.0
Marital status
 Married once 17 (85.0%) 3 (100.0%) 3 (75.0%) 19 (95.0%)
 Married more than once 3 (15.0%) 0 (0) 1 (25.0%) 1 (5.0%)
Partner’s marital status
 Married once 15 (75.0%) 2 (66.7%) 3 (75.0%) 17 (85.0%)
 Married more than once 5 (25.0%) 1 (33.3%) 1 (25.0%) 3 (15.0%)
Parity 3.0  2.0 3.5  0.5 4.0  1.0 2.0  2.0
Smoking status
 Smoking 3 (15.0%) 0 (0) 0 (0) 0 (0%)
 Not smoking 17 (85.0) 3 (100.0%) 4 (100.0) 20 (100.0%)
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Statistically, there was no significant difference
of retinol deposit sufficiency level between normal
cervix and cleared subclinical HPV infection
(p=0.628), normal cervix and persistent subclinical
HPV infection (p=0.078), normal cervix and
cervical cancer (p=0.433), cervical cancer and
cleared subclinical HPV infection (p=1.000),
cervical cancer and persistent subclinical HPV
infection (p=0.430), persistent subclinical HPV
infection and clearance (p=0.740).
As demonstrated on Table 2 and 3, there were
not significant differences in the level of retinol
adequacy deposits in all groups studied.
DISCUSSION
Statistically, there were no significant differences
in the level of retinol deposit sufficiency level in all
groups studied, such as between the normal cervix
and cervical cancer, normal cervix and persistent
subclinical HR-HPV infection, normal cervix and
cleared subclinical HR-HPV infection (p=0.433;
0.078; 0.628); cervical cancer and clearance
subclinical HR-HPV infection, cervical cancer and
persistent HR-HPV subclinical infection (p=1.000;
0.430), and subclinical HR-HPV infection
persistence and clearance (p=0.740).
In this study, we obtained the difference in the
sufficiency level of retinol deposit in the group of
subclinical infection with HR-HPV persistence,
clearance, and normal cervix (control). This result
was in accordance with predetermined clinical
justification. However, the result was far below
clinical justification for cervical cancer group.
Until now, the study of retinol in the immune
system related to the natural history of cervical
cancer was inconsistent, especially when applied to
population. There were many studies of
endogenous retinoid in plasma level on the natural
history of cervical cancer, there was still lack of
observation on the adequacy of retinol deposit.
This study showed that there was no statistically
significant difference of sufficiency retinol deposit
level in the group of normal cervix, cervical
subclinical HR-HPV infection clearance, persistent,
and cervical cancer. The results of this study were
relatively consistent with study conducted by
Siegel, et al.19 and Palan, et al.20 Siegel, et al. stated
that there was no significant association between
endogenous retinoic acid and a clearance of HPV
infection also cervical lesion regression. These
results indicated that the role of retinoic acid as an
HPV and carcinogenesis inhibitor in vitro could not
be demonstrated in epidemiological studies on the
setting of clinical population.19 Palan, et al. pointed
out that there were no significant differences in the
mean level of plasma retinol on 235 subjects with
normal cervix, cervical intraepithelial neoplasia
(CIN), and cervical cancer. The study also found
lower level of carotenoid and alfa-tocopherol in the
plasma of CIN and cervical cancer patients. There
was also significant linear trend in level of
carotenoid and alfa-tocopherol to degree of
cervical histopathological abnormalities.20 Another





Cervical Cancer 5 15 1.89 0.39 to 9.27 0.433
Persistent HR-HPV 2 1 11.33 0.76 to 167.97 0.078
Cleared HR-HPV 1 3 1.89 0.14 to 24.79 0.628
Control 3 17 Ref
Chi-Square test
Table 3. Relationship between the Deposit Adequacy Level of Retinol Group
Group (Sufficiency Rate Deposit of Retinol) OR IK (95%) p­value
Cervical Cancer vs Cleared HR-HPV 1.00 0.08-11.93 1.000
Cervical Cancer vs Persistent HR-HPV 0.17 0.01 to 2.26 0.430
Persistent HR-HPV vs Cleared HR-HPV 6.00 0.22 to 162.54 0.740
Chi-Square Test
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study by Giuliano, et al.21 stated that persistent
HPV infection could be inhibited by several anti-
oxidant micronutrients. Consumption of papaya
regularly at least once a week was associated with
significant barrier to persistence of infection.
Sedjo, et al.22 concluded that high consumption
of vegetables and fruits was related to 54%
decreased risk of HPV persistence. Goodmann,
et al.23 also found a significant correlation between
antioxidant level and the risk of CIN. Siegel, et al.
from another study also revealed contrary result
that retinol was not considered as a protective
agent against persistent infection with oncogenic
HPV on female population in Brazil.19 This
finding was also supported by Alvarez, et al.,24
who showed that there was no significant
difference in the rate of cervical lesion regression
in placebo, retinoid low dose, and high dose group.
Retinol regulates kind of essential cells in the
body. Retinoid plays an important role in the
process of growth, cleavage, tissues maintenance,
reproductive function, metabolism, differentiation,
haematopoietic, bone formation, spermatogenesis,
and embryogenesis. Deficiency of vitamin A will
impact to unwanted effects.25,23 Some factors
significantly affecting the level of endogenous
retinol include age,  race,  use o f  o r a l
c o n t r a c e p t i v e s ,  a n d  n u m b e r  o f
pregnancies.26 The concentration of retinoid did
not differ significantly between fasting and
non-fasting population.27
Dragnev, et al. stated that retinol had apoptosis
effect, anti-proliferative, and regulator of cell
differentiation, a chemo-preventive agent;28 thus,
it could be used in anti-cancer therapy. Retinol acts
via nuclear receptor to activate target genes
containing responsive element resulting to
biological effect. Anti-cancer activity of retinoid is
the result of three main mechanisms, such as
cytodifferentiation, growth cessation, and
apoptosis.28,29 Some retinoids are clinically
effective as chemo-preventive and anti-cancer
therapy in promielocytic acute leukemia, but, it
shows less effective against most solid tumors and
results unwanted side effects.23,29,30 Headache is
the most frequent adverse events after retinoid
treatment on approximately 74% of high doses of
retinoid.24 In combination with IFN, retinoid has
potential effect in cervical SCC. Retinoic
acid has the action as a radiosensitizer that
does not require the function of p53 in vitro.31
N a r a y a n a n ,  e t  a l .  s h o w e d  a n  increased
expression of p53 and inhibition of E6/E7
transcription after retinoid administration. This
finding suggested an important role of retinoic acid
as a cell cycle regulator, chemo-preventive, and
anti-viral agents.23,32,33
Our results had differences compared with
previous epidemiological studies, in which the
study showed the opposite relationship between
the  development  of  cancer  and v i tamin
A-containing diet. Systemic administration of
retinol can reduce the thickening of arterial intima
layer significantly after endothelial injury in vivo.
In vitro and in vivo, retinol has a pro-inflammatory
effect and it can enhance the expression of TNF-
as a cytokine that has an important role in acute
inflammation.31-33 Immunomodulating pharmaco-
logical concentration of vitamin A can lower the
incidence of tumor in experimental biochemistry.
Some studies proved that natural and synthetic
ret inoids  could  inhibi t  the  growth and
development of various tumor types.31
Apoptotic process includes a series of action that
is associated with retinoid. Geissmann, et al.
showed that retinoid could induce apoptosis
through its heterodimer receptor in spite of no
signal inflammation. The existence of cross
communication with inflammatory cytokines
allows retinoid to activate DNA-binding-factor-KB
in the core of dendritic cells, triggers MHC class II,
induces differentiation and maturation of dendritic
cells, as well as improves specific T-cell response
to antigens.34 Khan, et al. reported that human
keratinocytes (HKC), which had been immortalized
due to transfection of HPV-16, was more sensitive
to inhibition of retinoic acid compared with normal
HKC. Retinoic acid also can inhibit mRNA
expression of E6/ E7 and E2/ E5 HPV-16.
R e t i n o i c  a c i d  b e c a m e  b a r r i e r  t o
immortalization due to transfection of
HPV-16 and it reached up to 95%.35
Retinoic acid is a fraction of vitamin A in the
blood that is active in the process of cell
differentiation and growth. When the body
requires vitamin A, it will be mobilized from the
liver in the form of retinol by retinol binding
plasma (RBP). The uptake of retinol by various
cells of the body relies on receptor on the
membrane surface specifically to RBP. Later on,
retinol is transported through the cell membrane
and then it is tied to cellular retinol-binding protein
(CRBP) and RBP; finally, it will be released.36
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Retinol and vitamin A derivatives affect cell
differentiation, proliferation, and apoptosis, and
play an important physiological role in various
biological processes. Retinol is primary obtained
from animal products. Its intracellular
bioavailability is regulated by specific and CRBP.
The CRBP-1 as the most common CRBP isoform
is a small 15 KDa cytosolic protein that is highly
expressed in various tissues. It acts to regulate
absorption, esterification, and bioavailability of
retinol, also plays a major role in wound healing
and remodeling process of arteries. In recent
years, the role of retinoid signalling CRBP-1
during the development of cancer became the
aim of several studies.37 Expression of CRBP-1
is associated with cervical epithelial cell
differentiation. High amount of CRBP-1 could be
found in columnar and epithelial cells.38 The drop
of CRBP-1 was coincided with the disappearance
of retinol response in rat cervical epithelial cells.36
There are two types of retinol metabolism in the
smooth muscle cell. Increased production of
retinoic acid was found in the intima cell.37,39,40
Studies in vitro showed that the retinoid, in
particular 9-cis-RA, could inhibit the growth of
estrogen receptor through blocking the cell cycle.41
Synthetic retinoid is generally quite promising for
the treatment of cancer and several clinical trials
are also running, but only a few synthetic retinoid
have  been approved by  Food and Drug
Administration (FDA). Preclinical studies indicated
that synthetic retinoid inhibited the growth of
human cancer. Fenretinide (4-HPR) is one of the
most promising  ret inoid  c l in ical ly .  I t
demonstrated significant cytotoxic activity of
tumor cell through induction of apoptosis and
non-apoptotic routes.37,42
The pattern of CRBP-1 on human epithelial
endocervical is identic to those reported in mice.43
In addition, in humans, CRBP-1 was sufficient in
myometrium of non-pregnant women along with
protein CRABP; thus, they showed the role of ATRA
in proliferation control of the myometrium in vivo.
The level of CRBP-1 was down regulated on the
upper and lower segment of uterus during the first
and second trimesters of pregnancy.44 The CRBP-1
gene function in controlling the bioavailability of
vitamin A suggested that it might have particular
relevance in the inhibition of cancer transfor-
mation. However, in human cancer, the presence
and role of protein that specifically binded to
retinol and retinoic acid had not been widely
investigated. The dysregulation of CRBP-1
occcured in some tumors, such as breast tumors,
ovarian, endometrial, prostate, renal, cervical,
larynx ,  nasopharynx ,  lymphoma,  and
gastrointest inal  cancer .  Furthermore ,
hypermetilation of CRBP-1 was responsible for
the inactivation of some cancer cells. Thus,
epigenetic disruption of CRBP-1 was a
common event in human cancer and it might
have important implication for cancer prevention
and therapy of retinoid.37
Retinoid has long been used for the treatment
of psoriasis and acne. Retinoid is effective in some
pre-cancerous lesions, such as oral leukoplakia,
actinic keratosis, and cervical dysplasia. It is able
to delay the development of skin cancer in
individual with xerodermapigmentosum;
therefore, it shows chemopreventive potency.
Moreover, several malignancies have been treated
with retinoid-based therapy, as sole agent for
pathological promielocytic including acute
leukemia, Kaposi’s sarcoma, cutaneous T-cell
lymphoma, leukemia mielogenus juvenile chronic,
SCC, and kidney cancer.45,46
CONCLUSION
This study has proved that the normal cervix has
sufficient level of retinol deposit. However, this
study can not prove that cervical cancer and
persistent HPV infection have less retinol deposit.
These results provide important data on the
contribution of some previous studies on the role
of vitamin A that is still inconsistent as a chemo-
preventive measure in the natural history of
cervical  cancer .  Theoret ica l ly ,  ret inol
administration is expected to reduce the risk of
HR-HPV p e r s i s t e n c e  a n d  p r o g r e s s i o n
towards pre-cancerous lesion on the natural
history of cervical cancer. However, result of
this study would like to describe that there is
no association between adequacy of retinol
deposit and history of cancer. Therefore, based
on the result of this study, supplementation of
vitamin A can not become basic approach to
primary prevention of cervical cancer in terms of
nutrition.
RECOMMENDATION
Further studies with other isomers of retinoid,
such as retinoic acid should be conducted in
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relation to its sensitivity towards stimulation of
retinylpalmitate to activate mechanisms through
RAR. Retinol stimulation in vitro to activate
several parameters of local immune response in
cervical tissue is a promising study in the future.
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